A 70-gene microarray prognosis signature was previously discovered to improve the selection of patients with breast cancer for adjuvant therapy.(1,2) This diagnostic test known as “MammaPrint” was recently validated in an independent cohort and implementation was shown to be feasible in community hospitals.(3-7) MammaPrint was originally established on surgical resection specimens. Since most breast cancer patients will undergo core needle biopsies, we investigated whether the MammaPrint prognosis signature could be assessed in core needle biopsies.
Publication Name: Poster